HomeNewscoronavirusOmicron could be dominant in Europe by mid-January

Omicron could be dominant in Europe by mid-January

The European Union appears to be better positioned to face a new wave of infections this holiday season than last, when vaccinations had yet to begin in earnest.

December 16, 2021 / 20:29 IST
Story continues below Advertisement
United Kingdom | Image: Reuters
United Kingdom | Image: Reuters

Omicron could be the dominant coronavirus variant in Europe by mid-January, causing a surge in cases and likely increasing the number of hospitalizations and deaths, European Union officials said Wednesday.

“We are facing another Christmas in pandemic mode,” Ursula von der Leyen, the president of the European Commission, told lawmakers in the European Parliament in Strasbourg, France, noting that reports of new cases in the bloc were doubling every two to three days.

Story continues below Advertisement

ALSO READ: Omicron is very serious threat, what we know is bad: UK health official

Her speech and an assessment by the European Centre for Disease Prevention and Control painted a grim picture of the state of the pandemic on the continent, where many countries have recently reintroduced restrictions and scrambled to speed up vaccination campaigns.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show